Integrin Inhibitor

BIRT2584 is an LFA-1 inhibitor. BIRT2584 can be used for research on autoimmune diseases.

SAN-300 is a human IgG1 monoclonal antibody (mAb) targeting ITGA1/VLA-1. SAN-300 can be used in Rheumatoid arthritis research.

mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα₁₃ with integrin β₃ without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells.

αvβ6-IN-1 (compound 28) is a potent and orally active αvβ6 integrin inhibitor with a pIC₅₀ value of 8.1. αvβ6-IN-1 has the potential for the research of idiopathic pulmonary fibrosis.

BTT-3034, a sulfonamide derivative, is an α2β1 integrin inhibitor. BTT-3034 inhibits cell adhesion to rat tail collagen I with an EC₅₀ of 160 nM and a corresponding E_maxof 86%. BTT-3034 inhibits collagen binding by an α2 variant carrying the conformationally activating E318W mutation.

BT100 (sodium), a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis.

myr-RGT is a nutmeg acylated RGT peptide. myr-RGT can be used to inhibit extracellular signaling of integrin β3. myr-RGT can be used in the research of atherosclerosis and other related conditions.

RTDLDSLRTYTL TFA is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL TFA binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL TFA is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL TFA can be used in the research of cancer immunotherapy and targeted drug development.

αLβ2 integrin-IN-1 (example 1) is an αLβ2 integrin mediated cell adhesion inhibitor that can be used for the study of αLβ2 integrin mediated inflammatory conditions.

αvβ1 integrin-IN-2 (compound 32) is a potent inhibitor of integrins ανβ1 and α5β1 with IC₅₀s of 0.9 nM，and 33 nM，respectively. αvβ1 integrin-IN-2 also inhibits other integrins with ，，IC₅₀s of 380 nM (ανβ3)，280 nM (ανβ5)，230 nM (ανβ6)，87 nM (ανβ8)，respectively，in SPRA assay.

FR-158999 is a potent orally active fibrinogen inhibitor. FR-158999 exhibits potent anti-platelet activities with a pIC₅₀ of 7.50. FR-158999 can be used for antithrombotic research.

UR-3216 is a selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 has the potential for cardiovascular diseases research.

pUR4 is a recombinant peptide that acts as a fibronectin (FN) inhibitor. pUR4 binds to the N-terminal type I modules of fibronectin, inhibiting the polymerization of soluble fibronectin and its deposition into the extracellular matrix (ECM). pUR4 reduces β1 integrin activation by depleting ECM fibronectin and disrupting FN-β1 integrin coupling. pUR4 attenuates TNF-α-induced endothelial hyperpermeability, maintains endothelial monolayer integrity, and reduces TNF-α-induced cell morphological changes. pUR4 decreases neutrophil adhesion to cardiac endothelial cells, T cell interstitial migration, immune cell infiltration, collagen deposition, and fibroblast activation. pUR4 can be used in research on pathological vascular leakage, heart failure, inflammation, chronic kidney disease, liver fibrosis, and intestinal fibrosis.

Anti-Integrin α5β1 Antibody is an anti-human monoclonal antibody targeting integrin α5β1.

Anti-Mouse ICAM-1 Antibody (BE29G1) reacts with the mouse ICAM-1. Anti-Mouse ICAM-1 Antibody (BE29G1) blocks the binding LFA-1 (CD11a/CD18) to ICAM-1. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).

Excisanin A is a potent anticancer agent. Excisanin A inhibits cell proliferation, migration, adhesion and invasion. Excisanin A decreases the expression of MMP-2, MMP-9, p-FAK, p-Src, integrin β1 protein. Excisanin A has the potential for the research of breast cancer.

Grp94-IN-3 (Compound 47) is a selective ATP competitive inhibitor of Grp94, with a K_d value of 76 nM. Grp94-IN-3 has a much lower affinity for Hsp90α, with a K_d value of 9.17 μM. Grp94-IN-3 induces the degradation of integrin α2 (Integrin α2) in MDA-MB-231 cells and reduces the intracellular accumulation of mutant cardiac proteins in human trabecular meshwork cells. Grp94-IN-3 can be used for the study of metastatic cancer and open-angle glaucoma.

Anti-CD11b Antibody (ICRF44) reacts with the human CD11b. Anti-CD11b Antibody (ICRF44) recognizes the α subunit of the CD11b/CD18 complex, an α/β heterodimeric surface glycoprotein on human leukocytes. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).

αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect.

αvβ5 integrin-IN-3 is an orally active, selective αVβ5 integrin inhibitor with an IC₅₀ value of 0.61 nM. αvβ5 integrin-IN-3 inhibits αVβ1, αVβ3 and αVβ6 integrins with IC₅₀ values of 21 nM, 5.5 nM and 18 nM, respectively. αvβ5 integrin-IN-3 reduces total Collagen content in a mouse unilateral ureteral obstruction model. αvβ5 integrin-IN-3 can be used for the research of renal fibrosis.